[1]裴育,巴建明. 1型和2型糖尿病与骨质疏松症的关系[J]. 中华糖尿病杂志,2016,23(1): 12-14.
[2]王覃,陈德才. 糖尿病对骨质疏松症的影响及其机制[J]. 中华糖尿病杂志,2016,23(1): 5-7.
[3]Vestergard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes a meta-analysis [J]. Osteoporo Int, 2007, 18(2): 427-444.
[4]Tolosa MJ, Chuguransky SR, Sedlinsky C, et al. Insulin-deficient diabetes-induced bone microarchitecture alteration are associated with a decrease in the osteogenic potential of bone marrow progenitor cells: preventive effects of metformin [J]. Diabetes Res Clin Pract, 2013, 101(2): 177-186.
[5]Fontaine LJ, Chen C, Hunt N, et al. Type 2 diabetes and metformin influence on fracture healing in an experimental rat model [J]. J Foot Ankle Surg, 2016, 55(5): 955-960.
[6]Zhen D, Chen Y, Tang X. Metformin reverses the deleterious effects of high glucose on osteobalst function [J]. J Diabetes Complications,2010, 24(5): 334-344.
[7]Mai QG, Zhang ZM, Xu S, et al. Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblast and ovariectomized rats [J]. J Cell Biochem, 2011, 112(10): 2902-2909.
[8]UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes [J]. Lancet, 1998, 352(9131): 854-865.
[9]Garber AJ, Duncan TG, Goodman AM, et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial [J]. Am J Med, 1997,103(6): 491-497.
[10] Zinman B, Haffner SM, Herman WH, et al. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes [J]. J Clin Endocrinol Metab, 2010, 95(1): 134-142.
[11]魏开惠,王振华. 二甲双胍对2型糖尿病患者骨代谢的影响[J]. 实用临床医药杂志,2015,19(13): 117-118.
[12]Kasai T, Bandow K, Suzuki H, et al. Osteoblast differentiation is functionally associated with decreased AMP kinase activity [J]. J Cell Physiol, 2009, 221(3): 740-749.
[13]Shu A, Yin MT, Stein E, et al. Bone structure and turnover in type 2 diabetes mellitus [J]. Osteoporos Int, 2012, 23(2): 635-641.
[14]Schurman L, Mccarthy AD, Sedlinsky C, et al. Metformin reverts deleterious effects of advanced glycation end-products (AGEs) on osteoblastic cells [J]. Exp Clin Endocrinol Diabetes, 2008, 116(6): 333-340.
[15]Shah M, Kola B, Bataveljic A, et al. AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass [J]. Bone, 2010, 47(2): 309-319.
[16]Jang WG, Kim EJ, Bae KN, et al. Metformin induces osteoblast differentiation via orphan nuclear receptor SHP-mediated transactivation of Runx2 [J]. Bone, 2011, 48(4): 885-893. |